Clinical Trial Update: Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing the safety and efficacy of Biktarvy in subjects with the 184 resistance mutation; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)

Snippet

Sponsor: Southampton Healthcare, Inc. | Conditions: HIV-1-infection | Phase 4 | Status: TERMINATED